Migraine – Pipeline Review, H2 2018, provides an overview of the Migraine (Central Nervous System) pipeline landscape.
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.
Migraine – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 11, 16, 1, 24, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.
Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
REQUEST A SAMPLE REPORT:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Buy this report via Credit Card/Paypal or Wire Transfer:
Abide Therapeutics Inc
Achelios Therapeutics Inc
Acorda Therapeutics Inc
Alder Biopharmaceuticals Inc
Aralez Pharmaceuticals Inc
Astellas Pharma Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Biohaven Pharmaceutical Holding Company Ltd
Blackthorn Therapeutics Inc
Charleston Laboratories Inc
Corium International Inc
Eli Lilly and Co
Heptares Therapeutics Ltd
Impel NeuroPharma Inc
InKemia IUCT Group SA
InStar Technologies AS
Ionis Pharmaceuticals Inc
Klaria Pharma Holding AB
Merck & Co Inc
NAL Pharmaceuticals Ltd
Pivot Pharmaceuticals Inc
Promius Pharma LLC
Revance Therapeutics Inc
Sarfez Pharmaceuticals Inc
Shin Nippon Biomedical Laboratories Ltd
Sorrento Therapeutics Inc
Suda Pharmaceuticals Ltd
Teva Pharmaceutical Industries Ltd
Xenon Pharmaceuticals Inc
Xoc Pharmaceuticals Inc
Zosano Pharma Corp
Ritesh Tiwari, Director
Follow us on Social Media: